
STRO Stock Forecast & Price Target
STRO Analyst Ratings
Bulls say
Sutro Biopharma Inc is advancing its portfolio of biopharmaceutical products, with preclinical data indicating significant improvements in anti-tumor activity and safety profiles for its candidates, such as STRO-004 and STRO-006. The company is optimizing its capital allocation through a substantial workforce reduction of approximately 50%, which is projected to cut operating expenses by 50-70% starting in Q2 2025, enhancing financial sustainability through 2026. The innovative design of their pipelines, particularly for the integrin β6 ADC, positions Sutro favorably against competitors, potentially unlocking superior therapeutic advantages in the oncology market.
Bears say
Sutro Biopharma has recently experienced significant headwinds, including a net loss of $227.4 million for FY24, equivalent to $2.96 per share, which raises concerns about its financial stability moving forward. The company's decision to undertake a near-50% reduction in headcount and discontinuation of the luvelta program reflects a strategic refocusing that may hinder its product pipeline and future revenue potential. Additionally, the risks associated with achieving clinical results, competitor advancements, and reimbursement challenges further compound the negative outlook on the company's financial performance and stock valuation.
This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
STRO Analyst Forecast & Price Prediction
Start investing in STRO
Order type
Buy in
Order amount
Est. shares
0 shares